Schlieren ZH – Memo Therapeutics presents positive long-term data for its therapeutic antibody Potravitug at the end of the phase II study “Safe Kidney”. It is to be the first drug to be launched on the market to combat infections with the BK virus in recipients of transplanted kidneys.
(CONNECT) Memo Therapeutics presented positive long-term follow-up data from its Phase II "Safe Kidney" study with the therapeutic antibody potravitug at the American Society of Nephrology's Kidney Week, which runs through November 9, 2025 in Houston. It is used to treat BK polyomavirus (BKPyV) infections in recipients of transplanted kidneys, known as BK nephropathy.
According to a press release from the Bio-Technopark Schlieren-Zurich spin-off of the Swiss Federal Institute of Technology in Zurich, the viral load at week 38 was significantly lower than at week 20, meaning that the number of subjects with a 90 or 99 percent reduction in viral load at the follow-up point at week 38 had increased significantly, "indicating a longer-lasting response and a reduction in viral load with potravitug".
"These long-term Phase II follow-up results provide further evidence that potravitug has the potential to become a breakthrough treatment for kidney transplant patients with BKPyV infection, with sustained therapeutic benefit beyond our initial week 20 data," Erik van den Berg, CEO of Memo Therapeutics, is quoted as saying. "Currently, there are no approved therapeutic treatments for BKPyV infections in kidney transplant recipients. We look forward to continuing discussions with regulatory authorities and entering Phase III development in 2026."
In early August 2025, the biotech company announced the results of its placebo-controlled Phase II clinical trial with Potravitug in San Francisco. According to a press release published at the time, the study had shown a biopsy-confirmed cure of BK nephropathy in kidney transplant recipients. ce/mm
You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Turnstile. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More Information